. Author manuscript; available in PMC: 2014 Sep 10.

Published in final edited form as: J Thorac Oncol. 2013 Jul;8(7):823–859. doi: 10.1097/JTO.0b013e318290868f

TABLE 2.

Randomized Clinical Trial Data on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Versus Chemotherapy as First-Line Therapy for Patients With EGFR-Lung Cancers

Study	No. of Patients With EGFR-Mutated Lung Cancers	Response Rate (EGFR TKI Versus Chemotherapy), %	Progression-Free Survival (EGFR TKI Versus Chemotherapy), mo
EURTAC²⁸⁰	173 (86 erlotinib and 87 chemo)	58 versus 15	9.7 versus 5.2 (HR 0.37)
OPTIMAL²⁸¹	154 (82 erlotinib and 72 chemo)	83 versus 36	13.1 versus 4.6 (HR 0.16)
NEJ 002⁹¹	228 (114 gefitinib and 114 chemo)	74 versus 31	10.8 versus 5.4 (HR 0.30)
WJTOG3405²⁶	117 (58 gefitinib and 59 chemo)	62 versus 32	9.2 versus 6.3 (HR 0.49)
IPASS⁷⁹⁰	261 (132 gefitinib and 129 chemo)	71 versus 47	9.5 versus 6.3 (HR 0.48)
LUX LUNG3²⁸²	345 (230 afatinib and 115 chemo)	56 versus 23	11.1 versus 6.9 (HR 0.58)

Abbreviations: Chemo, chemotherapy; HR, hazard ratio.